BRCA1 expression in triple negative sporadic breast cancers

Analytical and Quantitative Cytology and Histology

Volumn 32, Issue 1, 2010, Pages 24-29

  Galizia, Eva ^a   Giorgetti, Gessica ^a   Piccinini, Gina ^a   Santinelli, Alfredo ^a   Loretelli, Cristian ^a   Bianchi, Francesca ^a   Gagliardini, Daniela ^a   Carbonari, Giovanna ^b   Pisa, Eleonora ^a   Belvederesi, Laura ^a   Bracci, Raffaella ^a   Ferretti, Concetta ^a   Corradini, Fabio ^a   Cellerino, Riccardo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Civile di Senigallia   (Italy)

Author keywords

BRCA1; Breast cancer; Somatic inactivation

Indexed keywords

BRCA1 PROTEIN; GENOMIC DNA; MESSENGER RNA;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 77951129391     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Natl Rev Cancer 2004;4:665-676
2. Honrado E, Benítez J, Palacios J: The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol 2005;18:1305-1320
3. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL: BRCA1 promoter methylation in sporadic breast tumors: Relationship to gene expression profiles. Breast Cancer Res Treat 2005;91:179-186
4. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y: BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-122
5. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T, Ushijima T: Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 2002;32:79-84
6. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054
7. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Natl Rev Cancer 2004;4:814-819
8. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-569
9. Knudson AG: Two genetic hits (more or less) to cancer. Natl Rev Cancer 2001;1:157-162
10. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006;8:R38
11. Catteau A, Harris WH, Xu CF: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 1999;18:1957-1965
12. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:165-168
13. Tassone P, Blotta S, Palmieri C, Masciari S, Quaresima B, Montagna M, D'Andrea E, Eramo OP, Migale L, Costanzo F, Tagliaferri P, Venuta S: Differential sensitivity of BRCA1 mutated HC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 2005;26:1257-1263
14. Sobin LH, Witteking CH (editors): TNM Classification of Malignant Tumors. Sixth edition. New York, International Union Against Cancer, 2002
15. Wilson CA, Payton MN, Pekar SK, Zhang K, Pacifici RE, Gudas JL, Thukral S, Calzone FJ, Reese DM, Slamon DI: BRCA1 protein products: Antibody specificity. Nat Genet 1996;12:303-308
16. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132
17. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;8:235-244
18. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of human BRCA1 and its loss in high-grade, noninherited breast carcinomas. Nature Genet 1999;21:236-240
19. Niwa Y, Oyama T, Nakajima T: BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 2000;91:519-526
20. Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 2004;22:4632-4642
21. Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002;21:5496-5503